A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol

Hannah Swayze, Julie Allen, Pedro Folegatti, Ly-Mee Yu, Sarah Gilbert, Adrian Hill, Chris Ellis, Christopher C Butler, Hannah Swayze, Julie Allen, Pedro Folegatti, Ly-Mee Yu, Sarah Gilbert, Adrian Hill, Chris Ellis, Christopher C Butler

Abstract

Seasonal influenza has a significant annual global impact. Current influenza vaccines work by inducing strain-specific antibodies against the highly polymorphic surface proteins of the influenza virus and need to be redesigned every year, increasing their cost and limiting availability. There is a demand for a more efficacious vaccine, particularly in older adults in which the current vaccines show poor efficacy. The aim is to investigate a novel vaccine, MVA-NP+M1, which targets T cell responses to the nucleoprotein and matrix 1 core proteins of the influenza virus A, which are highly conserved, and therefore may provide long protection against a broad range of influenza strains. INVICTUS is a phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above is a randomised, participant-blinded, placebo-controlled, multi-centre phase IIb efficacy study planned for 2030 volunteers aged 65 and over, in primary care. The primary objective is to assess the efficacy of MVA-NP+M1 co-administered with licensed inactivated quadrivalent influenza vaccine in adults ≥65 years. Participants complete daily diaries to record solicited and unsolicited events in the first four weeks post vaccination, and influenza-like illness (ILI) symptoms and severity throughout the influenza season. We hypothesise an improvement in the primary outcome, a reduction in the average number of days spent with moderate or severe influenza-like illness during periods of influenza circulation, in the group administered with MVA-NP+M1, compared to those in the control group. Registration: ClinicalTrials.gov identifier NCT03300362. Protocol version: INVICTUS Protocol v3.0, 08 June06 2018.

Keywords: Influenza; MVA-NP+M1; infection; older adults; primary care; vaccination.

Conflict of interest statement

Competing interests: Prof Sarah Gilbert and Prof Adrian Hill are scientific co-founders of the sponsoring institution named Vaccitech

Copyright: © 2019 Swayze H et al.

References

    1. WHO: Influenza. fact sheet No. 211.2014.
    1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. : The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–96. 10.1016/j.vaccine.2007.03.046
    1. Babakir-Mina M, Balestra E, Perno CF, et al. : Influenza virus A (H5N1): a pandemic risk? New Microbiol. 2007;30(2):65–78.
    1. Bardenheier BH, Strikas R, Kempe A, et al. : Influenza vaccine supply, 2005-2006: did we come up short? BMC Health Serv Res. 2007;7:66. 10.1186/1472-6963-7-66
    1. Hannoun C, Megas F, Piercy J: Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103(1–2):133–8. 10.1016/j.virusres.2004.02.025
    1. Hayward AC, Wang L, Goonetilleke N, et al. : Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med. 2015;191(12):1422–31. 10.1164/rccm.201411-1988OC
    1. Sridhar S, Begom S, Bermingham A, et al. : Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19(10):1305–12. 10.1038/nm.3350
    1. Berthoud TK, Hamill M, Lillie PJ, et al. : Potent CD8 + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7. 10.1093/cid/ciq015
    1. Lillie PJ, Berthoud TK, Powell TJ, et al. : Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012;55(1):19–25. 10.1093/cid/cis327
    1. Swayze H: F1000Research INVICTUS Protocol Manuscript.2019. 10.17605/
    1. : Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine.2013;31(50) : 10.1016/j.vaccine.2013.09.063 6030-3 10.1016/j.vaccine.2013.09.063
    1. : Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews.2018; 10.1002/14651858.CD004876.pub4 10.1002/14651858.CD004876.pub4
    1. : Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine.2014;32(44) : 10.1016/j.vaccine.2014.08.031 5816-23 10.1016/j.vaccine.2014.08.031

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere